Research programme: metalloenzyme inhibitors - Viamet Pharmaceuticals

Drug Profile

Research programme: metalloenzyme inhibitors - Viamet Pharmaceuticals

Alternative Names: VT 1598

Latest Information Update: 15 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Viamet Pharmaceuticals
  • Class Anti-inflammatories; Antifungals; Antineoplastics; Small molecules
  • Mechanism of Action 14-alpha demethylase inhibitors; Cytochrome P 450 enzyme system inhibitors; Enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Coccidioidomycosis
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Coccidioidomycosis
  • Research Inflammation; Mycoses

Most Recent Events

  • 13 Jul 2017 VT 1598 receives Fast Track designation for Coccidioidomycosis [PO] in USA
  • 15 Sep 2016 Research programme: metalloenzyme inhibitors (VT 1598) - Viamet Pharmaceuticals receives Qualified Infectious Disease Product status for Coccidioidomycosis in USA
  • 25 May 2016 VT 1598 receives Orphan Drug status for Coccidioidomycosis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top